UPC Analytics
ENDE
Analytics1Cases1Decisions4Judges9Parties2Firms
Filing trendsOutcomesPendencyTechnologyForum strategyLeading casesLegal issuesSecurity for costs

Outcome base rates

What's normal — PI grant rate, infringement rate, revocation rate, settlement rate. Honest denominators using motion type.

Legal principlePurposive claim construction — scope of second medical use claimClear all
Patentee win rate
Share of merits decisions where the patentee prevailed — infringement cases finding infringement, revocation cases upholding the patent. Settled, withdrawn, and procedural-only outcomes excluded from the denominator.
0%patentees prevail on the merits

1 merits decision (small sample)

0 won · 1 lost · Insufficient prior-period data

Win rate by year
Patentee win rate by year of first decision.
  • 2025: 0% (0/1)
Win rate by division
Top divisions by merits-decision volume.
  • Dusseldorf LD
    0%
    (n=1)
When patentees lose, why?
Of 1 loss…
100%
Patent invalidated — 0 (0%)No infringement found — 1 (100%)
PI grant rate
—
PI grant rate (conservative)
—
Infringement rate
0%
0 infringed · 1 not infringed
Revocation rate
—
Settlement / withdrawal rate
Settled / withdrawn / dismissed as a share of all non-pending outcomes.
0% 0 / 1
Outcomes by category (detailed)
Stacked breakdown using sharper outcome enums — revocation cases split into revoked_full / revoked_partial / maintained_as_*, etc.
By technology sector
Top sectors by case count (filter scope applied).
By case category
How outcome rates differ across the six L2 buckets.
  • Infringement1
By division
PI grant rate · infringement rate · revocation rate per division (within scope).
  • Dusseldorf LD1 casesPI grant rate: —Infringement rate: 0%Revocation rate: —
Recent decisions
Most recent decisions in scope.
  • 2025-05-13ACT_597355/2023Not infringedThe Düsseldorf Local Division dismissed Sanofi and Regeneron's infringement action and Amgen's counterclaim for revocation concerning EP3536712 (a second medical use patent for evolocumab in paediatric patients), finding no infringement of the second medical use claim and that the counterclaim for revocation was also unfounded, with each side bearing the costs of the proceedings they lost.